NEW YORK, May 12 (GenomeWeb News) - The European Vascular Genomics Network -- a European Union-funded initiative under the 6th Framework for technology research and development -- began operations this week, Inserm, the French National Institute of Health and Medical Research announced.
The network of excellence, fueled with €59 million ($70 million) funding with €9 million provided by the EU over five years, includes some 25 basic and clinical institutions, two biotechnology companies, and one management company from 10 EU member or associated states. Alain Tedgui of Inserm is the network coordinator. (Click here for a list of the participants).
The research activities of EVGN will concentrate research on three areas of cardiovascular disease and therapy: endothelial dysfunction in the development of atherosclerosis; the instability of the atherosclerotic plaque at the root of arterial thrombus formation; and therapeutic angiogenesis.
The organization plans a series of workshops, starting with the "Genomics and Proteomics of Plaque Instability," on Friday, May 14, at the Sheraton Hotel at Amsterdam's Schiphol airport.